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ABSTRACT
Background    The options for the treatment of nonalco-
holic steatohepatitis (NASH) are limited. We examined 
the effects of ipragliflozin, a sodium-glucose cotrans-
porter 2 inhibitor, on the fatty liver Shionogi (FLS)-ob/
ob mice, a non-alcoholic steatohepatitis mouse model.
Methods    FLS-ob/ob male mice were treated with ve-
hicle (n = 10) and ipragliflozin (n = 8). Serum metabolic 
markers, histopathology of the liver, hepatic cholesterol 
and triglyceride levels and hepatic mRNA levels related 
to fibrosis, lipid metabolism and endoplasmic reticulum 
(ER) stress were compared between the two groups.
Results    The body weight and hepatic cholesterol and 
triglyceride levels were significantly decreased in the 
ipragliflozin group compared with the control group. 
Hepatic steatosis and fibrosis were significantly amelio-
rated by the treatment with ipragliflozin. Hepatic infil-
tration of macrophage, expression levels of 8-hydroxy-
2-deoxyguanosine (8-OHdG) and hepatic mRNA levels 
of ER stress markers were not significantly modulated 
by the treatment with ipragliflozin.
Conclusion    Ipragliflozin can be a therapeutic option 
for patients with NASH. The precise mechanisms of 
action need to be clarified in future studies.
Key words    ipragliflozin; non-alcoholic steatohepatitis; 
sodium-glucose cotransporter 2 inhibitor
Nonalcoholic steatohepatitis (NASH) is a subtype of 
nonalcoholic fatty liver disease (NAFLD) which can 
progress to liver cirrhosis and cancer. Among the situ-
ation that the number of patients with NASH has been 
increasing worldwide, several novel drugs are under 
clinical trials including an inhibitor of apoptosis signal-
regulating kinase-1 (ASK-1), a farnesoid X receptor 
(FXR) agonist and a fibroblast growth factor (FGF)-
19 agonist.1, 2 Since there are no established treatments 
for NASH as of 2018, the application of novel drugs for 
NASH is long-awaited.
 Sodium-glucose cotransporter 2 (SGLT2) inhibitors 
are a new class of oral anti-diabetic agents which inhibit 
SGLT2-mediated renal glucose reabsorption and induce 
glycosuria. In addition to the lowering effects on blood 
glucose levels and body weight, some SGLT2 inhibitors 
(empagliflozin and canagliflozin) have been shown to 
improve cardiovascular outcomes in high-risk indi-
viduals and to slow the progression of diabetic kidney 
disease.3 Recently, SGLT2 inhibitors have also been 
demonstrated to benefit the liver in mouse models of 
NASH4, 5 and patients with NASH.6, 7 However, the pre-
cise mechanisms by which SGLT2 inhibitors ameliorate 
NASH are largely unknown.
 We have previously reported that the fatty liver 
Shionogi (FLS)-ob/ob mice made by transferring the 
leptinob gene develop steatohepatitis with increased oxi-
dative stress and fibrosis.8 By employing the FLS-ob/ob 
mice as a mouse model of NASH, we investigated the 
effects of ipragliflozin, a sodium-glucose cotransporter 
2 inhibitor, on the liver and explored the mechanisms of 
the actions.
MATERIALS AND METHODS
Animals and treatment with ipragliflozin
A total of 18 male FLS-ob/ob mice obtained from 
Shionogi Research Laboratories (Shiga, Japan) were 
housed in a room-controlled environment (temperature 
of 24 ± 2 °C and a 12-h light/dark cycle). The mice were 
allowed access to water and standard pellet chow (CE-
2, 4.6% fat; CLEA Japan, Tokyo, Japan) ad libitum. 
All experiments were performed in accordance with 
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the Animal Experimentation Guidelines of Tottori 
University (h26-Y-008).
 Eighteen FLS-ob/ob mice (12 weeks old) were 
divided into 2 groups; the control group (n = 10) and 
ipragliflozin group (n = 8). Mice in the ipragliflozin 
group were administered ipragliflozin orally at a dose of 
1 mg/kg via a gastric tube every day for 12 weeks. The 
control group received vehicle, a standard pellet chow, 
instead of ipragliflozin via a gastric tube every for 12 
weeks. After 12 weeks, the mice were sacrificed under 
pentobarbital anesthesia injection (Dainippon Sumitomo 
Pharma, Osaka, Japan) and blood was collected from 
the right ventricle. The plasma samples were frozen and 
stored at −80 °C. The liver and visceral fat tissues were 
collected, weighed, snap frozen in liquid nitrogen and 
stored at −80 °C. Liver specimens were fixed in 10% 
buffered formalin (Wako Pure Chemical Industries, 
Osaka, Japan) and embedded in paraffin (Wako Pure 
Chemical Industries) for histological analysis. 
Biochemistry
The blood samples were immediately separated by 
centrifugation at 2000 g for 15 min at 4 °C and stored at 
−80 °C until further use. Plasma levels of alanine ami-
notransferase (ALT), cholesterol and triglyceride were 
measured using an autoanalyzer (7170; Hitachi, Tokyo, 
Japan). 
Histopathology of the liver
Four-µm-thick sections of formalin-fixed and paraffin-
embedded liver were stained with hematoxylin-eosin 
(HE) for evaluation of lipid drops and picrosirius red 
counterstained with fast green for evaluation of fibrosis, 
respectively. The area of lipid drops and fibrosis was 
measured per specimen in 10 randomly selected fields/
section (magnification x200) by Win ROOF ver. 5.71 
(Mitsutani, Tokyo, Japan) and Olympus BX51N-34 mi-
croscope (Olympus, Tokyo, Japan).
Hepatic cholesterol and triglyceride levels
Snap frozen liver samples (50 mg) were homogenized, 
mixed with chloroform-methanol mixture (2:1 v/v; 
Wako Pure Chemical Industries), organic phase was 
dried and resolubilized in 2-propanol containing 10% 
Triton X-100. Total cholesterol and triglyceride levels 
were determined using commercial enzymatic kits 
(Cholesterol E-test and Triglyceride E-test; Wako Pure 
Chemical Industries).
RNA extraction and reverse transcription poly-
merase chain reaction (PCR)
Tissue samples were homogenized and total RNA was 
extracted using the RNeasy Mini Kit (Qiagen, Hilden, 
Germany). Concentrations of RNA were determined 
by measuring absorbance at 260 nm, and the quality 
of RNA was verified by electrophoresis on ethidium-
bromide-stained 1% agarose gels. Total RNA (2 μg) 
was reverse transcribed in a final volume of 11.5 μL 
containing 4 μL of 5x standard buffer, 2 μL of 0.1M 
dithiothreitol, 1 μL of SuperScript II RNase H-reverse 
transcriptase (Invitrogen, Carlsbad, CA), 2 μL of 10M 
dNTPs (Promega, Madison, WI), 1 μL of 50 pmol/
μL Random Primer (Promega), 0.5 μL of 100 pmol/
μL Oligo(dt)15 Primer (Promega) and 1 μL of 40 U/μL 
ribonuclease inhibitor (Wako Pure Chemical Industries, 
Osaka, Japan). Samples were incubated at 37 °C for 60 
min, 95 °C for 5 min and cooled to 4 °C for 5 min.
 Quantitative real-time PCR assays (7900HT Fast 
Realtime PCR system; Applied Biosystems, Carlsbad, 
CA) were proceeded in a final volume of 10 μL of solu-
tion containing 250 nM Universal ProbeLibrary probe 
(Roche, Basel, Switzerland), 900 nM forward primer, 900 
nM reverse primer, 5 μL EXPRESS qPCR Supermix 
with Premixed Rox (Invitrogen) and 2 μL cDNA. The 
mRNA levels of activating transcription factor 3 (ATF3) 
(GenBank; NM_007498.3), C/EBP-homologous protein 
(CHOP) (GenBank; NM_007837.3), C-JUN, nuclear pro-
tein 1 (NUPR1) (GenBank; NM_010591.2), peroxisome 
proliferator activated receptor-α (PPAR-α) (GenBank; 
NM_011144.6), procol lagen-type I (GenBank; 
NM_007742), sterol regulatory element-binding pro-
tein 1c (SREBP1c) (GenBank; NM_011480.3), tissue 
inhibitor of metalloproteinases-1 (TIMP-1) (GenBank; 
NM_001044384), transforming growth factor-β1 
(TGF-β1) (GenBank; NM_011577), and tumor necrosis 
factor-α (TNF-α) (GenBank; NM_013693.2) were as-
sessed using the 7900HT Fast Real-Time PCR System 
with SDS2.3 software (Applied Biosystems) and β-actin 
as an internal standard. Thermal cycle conditions were 
as follows: hold at 95 °C for 20 s followed by 45 cycles 
of 95 °C for 1 s and 60 °C for 20 s. The relative mRNA 
expression levels were compared using the 2-ΔΔCT 
method.
Inflammatory cells in the liver
Inflammatory cells in the liver was evaluated by immu-
nohistochemical staining with an anti-F4/80 monoclonal 
antibody (Abcam, Tokyo, Japan) in accordance with the 
manufacturer’s instructions. Immuno-positive cells were 
counted in 10 ocular fields (magnification x400) per 
specimen.
Oxidative stress in the liver
Oxidative stress in the liver was evaluated by immu-
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Table 1. The impact of ipragliflozin treatment on FLS-
ob/ob mice
Control
(n = 10)
Ipragliflozin
(n = 8) P value
Body weight (g) 58.0 ± 4.6 52.6 ± 4.5 0.024*
Liver weight (g) 7.36 ± 2.46 7.05 ± 2.80 0.110
Liver/body weight 
ratio 0.13 ± 0.03 0.13 ± 0.04 0.213
Visceral fat weight (g) 2.345 ± 0.395 2.385 ± 0.505 0.182
Serum ALT (U/L) 338.5 ± 187.5 263.5 ± 174.5 0.301
Serum cholesterol 
(mg/dL) 283.5 ± 60.5 321.5 ± 84.5 0.657
Serum triglyceride 
(mg/dL) 250 ± 126 313 ± 105 0.018*
Hepatic cholesterol 
(mg/dL) 69.0 ± 20.0 51.4 ± 15.6 0.003*
Hepatic triglyceride 
(mg/dL) 2479 ± 690 2182 ± 819 0.021*
*P < 0.05 compared with the control group.
FLS, fatty liver Shionogi.
Table 2. Hepatic mRNA levels in FLS-ob/ob mice 
treated with vehicle (control) and a SGLT2 inhibitor 
(ipragliflozin)
Control
(n = 10)
Ipragliflozin
(n = 8) P value
Procollagen I 1.35 ± 0.74 0.94 ± 0.71 0.062
TGF-β1 1.04 ± 0.44 0.90 ± 0.24 0.534
TIMP-1 0.98 ± 0.63 0.77 ± 0.48 0.131
TNF-α 0.76 ± 0.24 1.24 ± 0.69 0.016*
PPAR-α 1.42 ± 0.42 0.60 ± 0.28 0.0004***
SREBP1c 2.53 ± 1.53 1.75 ± 1.18 0.183
ATF3 0.74 ± 0.26 0.82 ± 0.56 0.214
CHOP 0.70 ± 0.30 0.80 ± 0.37 0.790
C-JUN 0.78 ± 0.26 0.77 ± 0.40 0.131
NUPR1 0.97 ± 0.41 0.81 ± 0.27 0.183
* P < 0.05, *** P < 0.001 compared with the control group.
ATF3, activating transcription factor 3; CHOP, C/EBP-homologous 
protein; C-JUN, jun proto-oncogene; FLS, fatty liver Shionogi; 
NUPR1, nuclear protein 1; PPAR-α, peroxisome proliferator activat-
ed receptor-α; SREBP1c, sterol regulatory element-binding protein 
1c; TGF-β1, transforming growth factor-β1; TIMP-1, tissue inhibitor 
of metalloproteinases-1; TNF-α, tumor necrotic factor-α.
nohistochemical staining with an anti-8-hydroxy-2-
deoxyguanosine (8-OHdG) monoclonal antibody 
(Nikken Seil, Shizuoka, Japan) according to the instruc-
tions from the manufacturer. Immuno-positive cells in 
10 ocular fields (magnification x400) per specimen were 
counted and the values were expressed as ratios (%) of 
fields. Analysis of immune-positive cells was carried out 
by using Win ROOF ver. 5.71 software.
Statistical analysis
The significance of differences between the groups was 
analyzed by the Mann-Whitney test. All statistical tests 
were performed using StatFlex ver. 6.0 for Windows 
software (Artech, Osaka, Japan). All values are ex-
pressed as means ± standard deviation. P < 0.05 was 
considered significant.
RESULTS
The impact of ipragliflozin treatment on FLS-ob/ob 
mice
After FLS-ob/ob mice were treated with vehicle (control 
group) and a SGLT2 inhibitor (ipragliflozin group) for 
12 weeks, several metabolic parameters were compared 
between the two groups (Table 1). The body weight 
and hepatic cholesterol and triglyceride levels were 
significantly decreased in the ipragliflozin group com-
pared with the control group. Serum triglyceride level 
was significantly higher in the ipragliflozin group than 
the control group. There was no significant difference 
between the two groups in the liver weight, liver to body 
weight ratio, visceral fat weight, serum ALT and choles-
terol levels. These results suggest that the treatment with 
ipragliflozin ameliorated fatty liver change in FLS-ob/ob 
mice.
Effects of ipragliflozin on hepatic steatosis
To confirm the above findings, hepatic steatosis levels 
in FLS-ob/ob mice were examined in the control and 
ipragliflozin groups. As expected, the area of hepatic 
steatosis was significantly decreased in the ipragliflozin 
group compared with the control group (P < 0.05, Figs. 
1A–C). 
 The molecular mechanisms of the inhibitory effects 
of hepatic steatosis by ipragliflozin were investigated 
by examination of the expression levels of PPAR-α 
and SREBP1c mRNA, which are relevant to hepatic 
steatosis, in the two groups of FLS-ob/ob mice (Table 
2). Expression levels of serum PPAR-α mRNA were 
significantly decreased in the ipragliflozin group com-
pared with the control group (P < 0.001) and those of 
SREBP1c were not different between the two groups.
Effects of ipragliflozin on liver fibrosis
The impact of ipragliflozin treatment on liver fibrosis 
in FLS-ob/ob mice was examined in the control and 
ipragliflozin groups. Sirius red staining revealed that 
area of liver fibrosis was significantly decreased in the 
ipragliflozin group compared with the control group 
(P < 0.001; Figs. 2A–C). The anti-fibrotic effect of 
ipragliflozin on the liver was substantiated by the result 
that hepatic mRNA levels of procollagen-1 tended to be 
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suppressed in the ipragliflozin 
group compared with the 
control group (Table 2).
 The molecular mecha-
nisms involved in the anti-
fibrotic effects of ipragliflozin 
were invest igated at the 
mRNA levels of TGF-β1 and 
TIMP-1. Hepatic expression 
levels of these molecules were 
not significantly modified by 
the treatment of ipragliflozin 
(Table 2).
Effects of ipragliflozin on 
hepatic infiltration of mac-
rophage
Because anti-inflammatory 
actions of SGLT2 inhibitors at 
the kidney level have been re-
ported,9 we evaluated whether 
ipragliflozin has impact on 
the infiltration of macrophage 
in the liver. The number of 
positive cells with F4/80, a 
representative marker of mac-
rophage (Kupffer cells), was 
examined in FLS-ob/ob mice 
(Figs. 3A–C). The number of 
F4/80-positive cells did not 
show a significant difference 
between the cont rol and 
ipragliflozin groups, although 
hepa t ic m R NA level of 
TNF-α, a pro-inflammatory 
cytokine, was significantly 
increased in the ipragliflozin 
group compared with the 
control group (Table 2). 
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Fig. 1. Effects of the treatment with ipragliflozin 
on hepatic steatosis in FLS-ob/ob mice. After 
FLS-ob/ob mice were treated with vehicle 
(control) and a SGLT2 inhibitor (ipragliflozin) 
for 12 weeks, hepatic steatosis levels were 
examined by hematoxylin-eosin (HE) staining. 
Representative pictures of each group are 
demonstrated. A: control group. B: ipragliflozin 
group. C: Quantification of hepatic steatosis 
levels by an image analysis system. ***P < 0.001. 
Bar = 100 μm. FLS, fatty liver Shionogi; SGLT2, 
sodium-glucose cotransporter 2.
Effects of ipragliflozin on oxidative stress and en-
doplasmic reticulum stress
Finally, we investigated the involvement of oxidative 
stress and endoplasmic reticulum (ER) stress in the 
inhibitory effect by ipragliflozin on liver steatosis and 
fibrosis in FLS-ob/ob mice. Since 8-OHdG has been re-
ported to be a hallmark of oxidative stress,10 expression 
levels of 8-OHdG in the liver was compared between 
the control and ipragliflozin groups (Figs. 4A–C). The 
number of 8-OHdG-positive cells was not significantly 
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Fig. 2. Effects of the treatment with ipragliflozin 
on liver fibrosis in FLS-ob/ob mice. After FLS-
ob/ob mice were treated with vehicle (control) and 
a SGLT2 inhibitor (ipragliflozin) for 12 weeks, 
liver fibrosis levels were examined by Sirius red 
staining. Representative pictures of each group are 
demonstrated. A: control group. B: ipragliflozin 
group. C: Quantification of hepatic fibrosis by an 
image analysis system. *** P < 0.001. Bar = 100 
μm. FLS, fatty liver Shionogi; SGLT2, sodium-
glucose cotransporter 2.
A
C
C
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changed by the treatment with ipragliflozin. As represen-
tative ER stress markers, we measured hepatic mRNA 
levels of ATF3, CHOP, C-JUN and NUPR1 (Table 2). 
Any of these ER stress markers were not changed by the 
treatment with ipragliflozin.
DISCUSSION
We examined the effects of ipragliflozin, a SGLT2 
inhibitor, on the metabolic factors and the liver in FLS-
ob/ob mice, a mouse model of NASH. We found that 
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Fig. 4. Effects of the treatment with ipragliflozin 
on oxidative stress. Expression levels of 8-OHdG 
were evaluated by immunohistochemical analy-
sis in FLS-ob/ob mice. Representative pictures of 
each group are demonstrated. A: control group. B: 
ipragliflozin group. C: The number of 8-OHdG-
positive cells was quantified and compared 
between the two groups. Bar = 100 μm. FLS, 
fatty liver Shionogi; 8-OHdG, 8-hydroxy-2-
deoxyguanosine.
Fig. 3. Effects of the treatment with ipragliflozin 
on hepatic infiltration of macrophage. The num-
ber of positive cells with F4/80, a representative 
marker of macrophage, was examined by im-
munohistochemical analysis in FLS-ob/ob mice 
using the anti-F4/80 antibody. Representative 
pictures of each group are demonstrated. A: 
control group. B: ipragliflozin group. C: The 
number of F4/80-positive cells was quantified 
and compared between the two groups. Bar = 
100 μm. FLS, fatty liver Shionogi.
treatment with ipragliflozin. This result may be because 
that fatty acids and fatty acid derivatives which serve as 
PPAR-α ligands15 were suppressed by ipragliflozin. 
 This study includes some limitations. One is that 
we were not able to clarify the mechanisms by which 
ipragliflozin improved hepatic fatty change and fibrosis. 
The other limitation is that we were not able to explore 
whether ipragliflozin could inhibit liver carcinogenesis 
in this NASH mouse model. 
 Finally, we explored the mechanisms of the benefitial 
C
C
B
the body weight of FLS-ob/
ob mice was significantly de-
creased by the treatment with 
ipragliflozin. This is consis-
tent with the data in a human 
study.11 We also observed that 
hepatic cholesterol and tri-
glyceride levels were signifi-
cantly decreased and serum 
cholesterol and triglyceride 
levels were increased after the 
treatment with ipragliflozin, 
which is in concordance with 
a previous report.12 We specu-
late that uptake of serum cho-
lesterol was decreased by the 
liver by ipragliflozin, because 
empagliflozin, another SGLT2 
inhibitor, has been demon-
strated to reduce hepatic ex-
pression levels of low-density 
lipoprotein cholesterol (LDL)-
receptor in hamsters.13
 It is contrary to previous 
studies in mice and human5–7, 11 
that serum ALT levels did not 
decrease after the treatment 
with ipragliflozin. This dis-
crepancy may derive from the 
differences in the experimen-
tal conditions.
 We have also demon-
strated that the treatment 
with ipragliflozin ameliorated 
liver fibrosis in FLS-ob/ob 
mice. Although we were not 
able to identify the molecular 
mechanisms involved in the 
anti-fibrotic effects of ipragli-
f lozin, the action appears 
to be mediated in a manner 
independent of TGF-β1 and 
TIMP-1.
 We found that hepatic steatosis levels in FLS-ob/ob 
mice were significantly ameliorated by the treatment with 
ipragliflozin in concordance with previous reports.5, 6, 11 
Since PPAR-α regulates the catabolism of fatty acids 
in the liver by inducing several proteins including fatty 
acid transport protein (FATP) and long-chain fatty acid 
acetyl-CoA synthase (ACS)14 and then benefits hepatic 
steatosis, it was unexpected that expression levels of 
PPAR-α mRNA were significantly inhibited by the 
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effects of ipragliflozin on the hepatic steatosis in FLS-ob/ob 
mice. Our data suggest that inflammation, oxidative stress 
and ER stress are not involved in the action. Although we 
were not able to clarify the precise mechanisms, our work 
shows that ipragliflozin could be a novel drug for the treat-
ment of hepatic steatosis and fibrosis in patients with NASH. 
The authors declare no conflict of interest.
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